Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase

Pharmacogenetics

Volumn 13, Issue 6, 2003, Pages 307-319

  Yu, Ai Ming ^a   Idle, Jeffrey R ^b   Herraiz, Tomas ^c   Küpfer, Adrian ^b   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Institute of Clinical Pharmacology   (Switzerland)

^c INSTITUTO DE FERMENTACIONES INDUSTRIALES CSIC   (Spain)

Author keywords

Beta carbolines; Cytochrome P 450 CYP2D6; Hydroxylation; O demethylating; Oxidoreductases; Phenylethylamines; Tryptamines

Indexed keywords

3 METHOXY 4 TYRAMINE; 4 METHOXY 3 TYRAMINE; 5 METHOXY N,N DIMETHYLTRYPTAMINE; 5 METHOXYINDOLETHYLAMINE O DEMETHYLASE; 6 METHOXYTRYPTAMINE; 6 METHOXYTRYPTOLINE; AMINE; ANILINE DERIVATIVE; BETA CARBOLINE; BETA CARBOLINE DERIVATIVE; CYTOCHROME P450 2D6; HARMAN; INDOLE DERIVATIVE; MELATONIN; METADRENALIN; MONOCLONAL ANTIBODY; NORFENEFRINE; NORMETADRENALIN; PHENYLEPHRINE; RECOMBINANT ENZYME; SEROTONIN; TRYPTOLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING ASSAY; BRAIN; CONTROLLED STUDY; DEMETHYLATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LIVER MICROSOME; MOUSE; NONHUMAN; PHENOTYPE; PINEAL BODY; PRIORITY JOURNAL;

ANIMALS; CARBOLINES; CYTOCHROME P-450 CYP2D6; HUMANS; MICE; OXIDOREDUCTASES, O-DEMETHYLATING; PHENETHYLAMINES; SUBSTRATE SPECIFICITY; TRYPTAMINES;

MUS MUSCULUS;

EID: 0038240578     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200306000-00002     Document Type: Article

References (81)

1. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2:584-586.
2. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90:11825-11829.
3. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 1999; 226:327-338.
4. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17:102-105.
5. Granvil CP, Krausz KW, Gelboin HV, Idle JR, Gonzalez FJ. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther 2002; 301:1025-1032.
6. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10:577-581.
7. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11:573-585.
8. Guengerich FP, Miller GP, Hanna IH, Sato H, Martin MV. Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps. J Biol Chem 2002; 277:33711-33719.
9. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
10. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002; 82:1376-1387.
11. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001; 11:237-245.
12. Thum T, Borlak J. Gene expression in distinct regions of the heart. Lancet 2000; 355:979-983.
13. Idle J. Pharmacogenetics. Enigmatic variations. Nature 1988; 331:391-392.
14. Idle JR, Mahgoub A, Lancaster R, Smith RL. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci 1978; 22:979-983.
15. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) 1982; 284:295-299.
16. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD. Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation. Am Heart J 1983; 105:159-161.
17. Oates NS, Shah RR, Idle JR, Smith RL. Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation. Lancet 1981; 1:837-838.
18. Eichelbaum M. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications]. Internist (Berl) 1983; 24:117-127.
19. Laine K, Tybring G, Hartter S, Andersson K, Svensson JO, Widen J, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001; 70:327-335.
20. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44:349-355.
21. Lessard E, Yessine MA, Hamelin BA, Gauvin C, Labbe L, O'Hara G, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21:175-184.
22. Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 2000; 49:549-554.
23. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. J Pharmacol Exp Ther 1997; 281:330-336.
24. Eichelbaum M, Spannbrucker N, Dengler HJ. Proceedings: N-oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedebergs Arch Pharmacol 1975; 287 Suppl:R94.
25. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16:183-187.
26. Spannbrucker N, Eichelbaum M, Steinke B, Dengler HJ. [A human genetic defect in the metabolism of sparteine]. Verh Dtsch Ges Inn Med 1978:1125-1127.
27. Küpfer A, Schmid B, Preisig R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984; 2:517-518.
28. Küpfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986; 16:421-433.
29. Schmid B, Bircher J, Preisig R, Küpfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38:618-624.
30. Lennard MS, Silas JH, Freestone S, Trevethick J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1982; 14:301-303.
31. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307:1558-1580.
32. Dayer P, Balant L, Courvoisier F, Küpfer A, Kubli A, Gorgia A, et al. The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet 1982; 7:73-77.
33. Yue QY, Svensson JO, Alm C, Sjoqvist F, Sawe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 1989; 28:639-645.
34. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990; 347:773-776.
35. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336:529-532.
36. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991; 1:33-41.
37. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331:442-446.
38. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45:889-904.
39. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60:522-534.
40. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
41. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8:15-26.
42. Yu A-M, Granvil CP, Haining RL, Krausz KW, Corchero J, Küpfer A, et al. The relative contribution of monoamine oxidase and cytochrome P450 isozymes to the metabolic deamination of the trace amine tryptamine. J Pharmacol Exp Ther 2003; 304:539-546.
43. Yu A-M, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13:173-181.
44. Yu A-M, Idle JR, Krausz KW, Küpfer A, Gonzalez FJ. Contribution of individual P450 isozymes to the O-demethylation of the psychotropic β-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 2003; 305:315-322.
45. Gelboin HV, Krausz KW, Shou M, Gonzalez FJ, Yang TJ. A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics 1997; 7:469-477.
46. Ho BT, Walker KE. 1,2,3,4-Tetrahydro-β-carboline. in: Noland WE (editor): Organic Syntheses: Collective volume 6. New York: John Wiley & Sons Inc.; 1988, pp 965-966.
47. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 2001; 60:1260-1267.
48. Krausz KW, Goldfarb I, Buters JT, Yang TJ, Gonzalez FJ, Gelboin HV. Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. Drug Metab Dispos 2001; 29:1410-1423.
49. Omura T, Sato R. The carbon-monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964; 239:2370-2378.
50. Bridges A, Gruenke L, Chang YT, Vakser IA, Loew G, Waskell L. Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase. J Biol Chem 1998; 273: 17036-17049.
51. Küpfer A, Al-Dabbagh SG, Ritchie JC, Idle JR, Smith RL. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. Biochem Pharmacol 1982; 31:3193-3199.
52. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998; 249:838-843.
53. Miller GP, Hanna IH, Nishimura Y, Guengerich FP. Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis. Biochemistry 2001; 40:14215-14223.
54. Gelboin HV, Krausz KW, Gonzalez FJ, Yang TJ. Inhibitory monoconal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. Trends Pharmacol Sci 1999; 20:432-438.
55. Mandel LR, Rosegay A, Walker RW, VandenHeuvel WJ, Rokach J. 5-Methyltetrahydrofolic acid as a mediator in the formation of pyridoindoles. Science 1974; 186:471-473.
56. Friedman E, Meller E, Hallock M. Effects of conformationally restrained analogues of serotonin on its uptake and binding in rat brain. J Neurochem 1981; 36:931-937.
57. Mackman R, Tschirret-Guth RA, Smith G, Hayhurst GP, Ellis SW, Lennard MS, et al. Active-site topologies of human CYP2D6 and its aspartate-301 → glutamate, asparagine, and glycine mutants. Arch Biochem Biophys 1996; 331:134-140.
58. Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC, et al. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 2003; 278:4021-4027.
59. Hadidi H, Güzey C, Idle JR: Pharmacogenetics and toxicological consequences of human drug oxidation and reduction, in Ballantyne B, Marrs T, Syversen T (editors): General and Applied Toxicology. Basingstoke: Macmillan Reference; 1999, pp 215-250.
60. Guengerich FP, Miller GP, Hanna IH, Martin MV, Leger S, Black C, et al. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 2002; 41:11025-11034.
61. Nygren LG, Fuxe K, Jonsson G, Olson L. Functional regeneration of 5-hydroxytryptamine nerve terminals in the rat spinal cord following 5, 6-dihydroxytryptamine induced degeneration. Brain Res 1974; 78:377-394.
62. Hartter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, et al. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin Pharmacol Ther 2001; 70:10-16.
63. Skene DJ, Papagiannidou E, Hashemi E, Snelling J, Lewis DF, Fernandez M, et al. Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. J Pineal Res 2001; 31:333-342.
64. Benington F, Morin RD, Clark LC, Jr. 5-methoxy-N,N-dimethyltryptamine, a possible endogenous psychotoxin. Ala J Med Sci 1965; 2:397-403.
65. Shulgin A, Shulgin A. TIHKAL. The Continuation. Berkeley: Transform Press; 1997.
66. McBride MC. Bufotenine: toward an understanding of possible psychoactive mechanisms. J Psychoactive Drugs 2000; 32:321-331.
67. Ott J. Pharmanopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J Psychoactive Drugs 2001; 33:273-281.
68. Takeda N, Ikeda R, Ohba K, Kondo M. Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders. Neuroreport 1995; 6:2378-2380.
69. Narasimhachari N, Heller B, Spaide J, Haskovec L, Fujimori M, Tabushi K, et al. Urinary studies of schizophrenics and controls. Biol Psychiatry 1971; 3:9-20.
70. Narasimhachari N, Heller B, Spaide J, Haskovec L, Meltzer H, Strahilevitz M, et al. N,N-dimethylated indoleamines in blood. Biol Psychiatry 1971; 3:21-23.
71. Forsstrom T, Tuominen J, Karkkainen J. Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS. Scand J Clin Lab Invest 2001; 61:547-556.
72. Cichon S, Nothen MM, Rietschel M, Propping P. Pharmacogenetics of schizophrenia. Am J Med Genet 2000; 97:98-106.
73. Airaksinen MM, Kari I. Beta-carbolines, psychoactive compounds in the mammalian body. Part I: Occurrence, origin and metabolism. Med Biol 1981; 59:21-34.
74. Airaksinen MM, Kari I. Beta-Carbolines, psychoactive compounds in the mammalian body. Part II: Effects, Med Biol 1981; 59:190-211.
75. Guchhait RB. Biogenesis of 5-methoxy-N,N-dimethyltryptamine in human pineal gland. J Neurochem 1976; 26:187-190.
76. van der Horst CJ, Ebels I. Extraction of pineal ard uterine tissue at different pH values: a preliminary report on the occurrence of a few groups of compounds in both tissues. Cytobios 1980; 29:191-203.
77. Leino M, Airaksinen MM. Methoxyindoles of the retina. Med Biol 1985; 63:160-169.
78. Thompson MA, Moon E, Kim UJ, Xu J, Siciliano MJ, Weinshilboum RM. Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization. Genomics 1999; 61:285-297.
79. Wyatt PJ, Erdelyi E, DoAmaral JR, Elliott GR, Renson J, Barchas JD. Tryptoline formation by a preparation from brain with 5-methyltetrahydrofolic acid and tryptamine. Science 1975; 187:853-855.
80. Rosengarten H, Meller E, Friedhoff AJ. Synthesis of tetrahydro-beta-carbolines from indoleamines via enzymatic formation of formaldehyde from 5-methyltetrahydrofolic acid. Biochem Pharmacol 1975; 24: 1759-1762.
81. Ratner S, Clarke HT. The action of formaldehyde upon cysteine. J Am Chem Soc 1937; 59:200-206.